RxDoctor Payments Data

Mona Daye

Psychiatric/Mental Health, Child & Adolescent · Morris, ILNPI 1619140316

Payments from drug & device makers

$3,703in general payments, 2019–2025

Across 175 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$488
  • E.r. Squibb & Sons, L.L.C.$466
  • Otsuka America Pharmaceutical, Inc.$328
  • Johnson & Johnson$310
  • Neurocrine Biosciences, Inc.$274
  • plus $759 from 9 others

What the payments were for

  • Food & beverage$3,703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychiatric/mental health, child & adolescent providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$21,766
Medicare patients
73
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate11$62,528
Abilify MaintenaAripiprazole17$43,476
Invega SustennaPaliperidone Palmitate11$36,127
Lurasidone Hcl22$5,801
Aripiprazole58$4,402
Quetiapine Fumarate144$2,073
Divalproex Sodium ErDivalproex Sodium27$1,909
Clozapine14$1,896
Oxcarbazepine42$1,876
Olanzapine81$1,527
Olanzapine OdtOlanzapine13$1,270
Risperidone112$1,182
Ziprasidone Hcl20$843
Trazodone Hcl122$801
Benztropine Mesylate96$790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$310$98,65522 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$328$43,47617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, child & adolescent providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other psychiatric/mental health, child & adolescent in Morris

Where these figures come from

Is this you, or does something look wrong? →